ADHERENCE ASSESSMENT: IDENTIFYING AND ADDRESSING POTENTIAL BARRIERS

Kathy W. Oubre, MS
Jody Pelusi, PhD, FNP, AOCNP
Kristine B. LeFebvre, MSN, RN, AOCN
DISCLOSURES

Nothing to disclose
OBJECTIVES

• Compare two oral oncolytic drug management programs as related to the initial assessment of patients prior to starting therapy.

• Identify three challenges faced by individuals in vulnerable populations.

• List 3 assessment tools/approaches for the ongoing evaluation of patient on oral oncolytic as related to adherence.
MODEL OF CARE – PELUSI’S MODEL, 1998

- Staff Education
- Patient Selection and pretreatment evaluation
- Treatment Plan Development
- Patient and Caregiver education
- QA, PQE, P & P Variance Reporting
- Patient and Staff Satisfaction
- Communication
- Documentation
- Monitoring and Follow up
- Reimbursement prescription refills, and acquisition of medication

ADHERENCE

Pelusi’s Model
ASSESSMENT

ASCO/ONS Chemotherapy Administration Safety Standards

• Pre-Treatment Assessment
  • Socioeconomic
  • Physical
  • Psychological
  • Regulatory barriers

• Informed Consent

• Monitoring and Adherence

(Neuss et al., 2016)
KEY POINTS

• Review the guidelines and recommendations
• Evaluate what you currently have
• Involve the whole team, including patients and caregivers in the development and evaluation process
• Communicate findings and process issues to all
• Trust the process
ASSESSMENT TOOLS


• Mini-Mental State Examination - www.heartinstitutehd.com/Misc/Forms/MMSE.1276128605.pdf

RESOURCES

• Oral Chemotherapy Education Sheets - http://oralchemoedsheets.com/


REFERENCES


• Neuss et al., 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards, Including Standards for Pediatric Oncology. *Journal of Oncology Practice*. Published online before print November 21, 2016. DOI: 10.1200/JOP.2016.017905

QUESTIONS?